Font Size

Pharmacy and Therapeutics Committee

The Mississippi Division of Medicaid’s Pharmacy and Therapeutics (P&T) Committee is comprised of twelve participating physicians, nurse practitioners, and practicing pharmacists who are active MS Medicaid providers and in good standing with their representative organizations. The P&T Committee is an advisory panel who conducts in-depth clinical evaluations and recommends appropriate drugs for preferred status on DOM’s Preferred Drug List (PDL) and/or drugs for prior authorization. Drugs and drug classes are evaluated for their safety, efficacy, and overall cost value and the committee will make subsequent recommendations to the Executive Director regarding prior authorization criteria for these drugs and classes.

The decision of the committee regarding any limitations to be imposed on any drug or its use for a specified indication shall be based on sound clinical evidence found in labeling, drug compendia, and peer reviewed clinical literature pertaining to use of the drug in the relevant population.

P&T Committee Meeting Information

The P&T Committee meets four (4) times annually. Meetings are held in room 145 of the Woolfolk Building located at 501 N. West Street, Jackson, MS 39201.

Registration is required for all pharmaceutical industry and advocacy representatives to be able to attend P&T Committee meetings. Registration opens 30 days prior to the meeting date and ends when registration limits have been reached or by noon the day before the meeting. Only one (1) representative per company may register/attend.

Medicaid’s Pharmacy & Therapeutics Committee meeting schedule:

2022 P&T meeting dates:

  • February 15, 2022 – 10:00am
  • May 10, 2022 – 10:00am (Meeting cancelled)
  • August 9, 2022 – 10:00am
  • October 18, 2022 – 10:00am

All meetings will be live with no virtual options.

P&T Committee Meeting Resources

CLICK HERE to register online! You must register to attend P&T Committee meetings.  Only one representative per company may attend. 

NOTE: Registration is required for all pharmaceutical industry and advocacy representatives to be able to attend P&T Committee meetings.

Companies that have met the one representative per company limit (as of September 22, 2022):

  1. AbbVie
  2. Alnylam
  3. Amgen
  4. Biogen
  5. Biohaven
  6. CSL Vifor
  7. Eli Lilly
  8. Evofem
  9. Gilead
  10. Indivior
  11. Janssen
  12. Marinus
  13. Medimpact
  14. Merck
  15. Mississippi Center for Advanced Medicine
  16. Neurelis
  17. Novartis
  18. Novo Nordisk
  19. Pierre Fabre
  20. Recordati Rare Diseases
  21. Regeneron
  22. Sarepta
  23. SOBI
  24. Supernus
  25. Teva
  26. UCB
  27. United Therapeutics Corp.
  28. Viatris
  29. Xeris


P&T Committee Meeting Minutes and AgendasArchive of Meeting Minutes and Agendas

Date P&T Meeting Minutes Meeting Agenda
Oct. 18, 2022 Minutes Agenda
Aug. 9, 2022 Minutes Agenda
Feb. 15, 2022 Minutes Agenda
Oct. 19, 2021 Minutes Agenda
Aug. 10, 2021 Minutes Agenda
May 11, 2021 (cancelled) Minutes Agenda

Preferred Drug List (PDL)

The preferred drug list is a medication list recommended to the Division of Medicaid (DOM) by the P&T Committee and approved by the Executive Director of the DOM. Drugs designated as preferred have been selected for their efficaciousness, clinical significance, cost effectiveness and safety for Medicaid beneficiaries. Most generic agents are preferred, do not require prior authorization and may not be individually listed. Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

Medicaid-covered drugs noted as “non-preferred” will continue to be available through the prior authorization process. A three-day emergency supply of prior-authorized drugs can be dispensed by a pharmacy until authorization is completed.

The PDL only addresses certain drug classes. Drugs which have historically been covered by Medicaid and are not listed on the Preferred Drug List will continue to be covered. Some drug classes will not be reviewed for preferred status because of no and/or limited cost savings, if the class is all and/or mostly generic, or if there is low utilization in that class. Be advised that DOM may opt to include or delete drug classes from PDL review in the future.

New drugs introduced into the marketplace in therapeutic classes that have been reviewed will be considered non-preferred until the annual review of the particular therapeutic class.

Important Information for Drug Manufacturers
Change Healthcare (CHC), has been awarded the contract for Preferred Drug List Maintenance and Supplemental Rebate Program for the Mississippi Division of Medicaid (DOM) effective July 1, 2016.

Change Healthcare
P.O. Box 1090
Augusta, ME 04332-1090

Industry Information Requests
Industry representatives with clinical inquires related to drugs listed on the Preferred Drug List may contact the Division’s clinical contractor, Change Healthcare (CHC). The primary contact at CHS for Mississippi Medicaid is:

Paige Clayton, Pharm.D.


P&T Committee Contacts

Please route inquiries regarding the P&T Committee to the Bureau of Pharmacy to the following.

Phone: (601) 359-5253